Trial Profile
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Feb 2021 Planned End Date changed from 15 Jan 2023 to 15 Apr 2024.
- 08 Feb 2021 Planned primary completion date changed from 15 Jan 2022 to 15 Apr 2023.